Medical Technology Breaking News: Ebola Patient Who Received Aethlon (OTCBB: AEMD) Hemopurifier® Therapy Has Been Discharged From Hospital

SAN DIEGO - November 25, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, disclosed today that an Ebola patient who received Hemopurifier® therapy has been reported to have been discharged from Frankfurt University Hospital in Germany. The patient was a Ugandan physician, who became infected with Ebola in Sierra Leone where he was treating other Ebola patients.

Medical Technology Breaking News: Time Magazine Names The Aethlon Hemopurifier® (OTCBB: AEMD) One of the 25 Best Inventions of 2014

SAN DIEGO - November 21, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, announced today that the Aethlon Hemopurifier® has been named one of the 25 best inventions of 2014 by Time Magazine. The article can be found on-line at the following link: http://time.com/3594971/the-25-best-inventions-of-2014

The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. To date, the device has been utilized in the treatment of Ebola, HIV and Hepatitis C virus. Time previously reported on the successful use of Hemopurifier® therapy in an Ebola patient with multiple organ failure. The article can be found on-line at the following link: http://time.com/3586271/ebola-treatment-dialysis-blood

Medical Technology Breaking News: Aethlon Medical (OTCBB: AEMD) Discloses Expanded Access "Emergency Use" Pathway to Treat Ebola in the United States

SAN DIEGO - November 19, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, disclosed today that it will provide Hemopurifier® therapy under FDA expanded access "emergency use" provisions to support requests from qualified physicians and institutes that may seek to treat ebola virus infection in the United States.

Aethlon previously disclosed that it would provide Hemopurifier® therapy on a humanitarian basis through FDA compassionate use access provisions, which allow for the use of an investigational device to treat an individual patient or small group based on clearance by FDA prior to treatment.

Breaking Tech News: NXT-ID (NASDAQ: NXTD) to Present at Upcoming LD Micro Conference December 3^rd

Gino Pereira, CEO of NXT-ID to Present Its Biometric Smart Wallet Technology

SHELTON, Conn. - November 19, 2014 (Investorideas.com Newswire) NXT-ID, Inc., (NASDAQ: NXTD), a biometric authentication company focused on the growing mobile commerce market announces it will present at the upcoming LD Micro conference on Wednesday, December 3rd, 2014 at 7:30 AM PST / 10:30 AM EST. Mr. Gino Pereira, CEO of NXT-ID will be discussing the Wocket™ smart wallet and its much anticipated launch.

The conference will be held December 2-4, 2014 at the Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, CA.

Gino Pereira, CEO of NXT-ID said, "The Company is very excited to present details on its biometric smart wallet, Wocket™, as we prepare to ship the first units to consumers. With the recent high profile launch of Apple Pay into the smart wallet payment services sector, there is significant investor and consumer interest in the next generation of payment technologies."